Fund marks imply 1/98 of the round — treated as a units change, held — shown at a merger or acquisition, Apr 2026 ($1.1B post-money).
- ·35 fund marks: filer, period, implied $/share
Membership and data by Private Market View
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Neurona Therapeutics funding history
6 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Mar 2025 | Later Stage VC (Series F) | $101.7M | ▮ | ▮ |
| Feb 2024 | Later Stage VC (Series E) | $120.0M | ▮ | ▮ |
| Mar 2021 | Later Stage VC | $72.0M | ▮ | ▮ |
| Nov 2019 | Early Stage VC | $15.0M | ▮ | ▮ |
| Feb 2018 | Early Stage VC | $10.0M | ▮ | ▮ |
| Dec 2014 | Early Stage VC | $28.7M | ▮ | ▮ |
Membership and data by Private Market View
Neurona Therapeutics valuation
Neurona Therapeutics is valued at approximately $1.1 billion as of Oct 2026. The figure is set by institutional fund marks. The reference point is a merger or acquisition in Apr 2026, at a $1.1 billion post-money valuation.
Recent activity
In the last 90 days, Neurona Therapeutics's record added 15 institutional fund marks (latest period Jul 2026).
How much has Neurona Therapeutics raised?
Neurona Therapeutics has raised $348 million across 6 recorded rounds since 2014. The largest was a $72 million later-stage round in Mar 2021; the most recent was a $102 million Series F in Mar 2025.
Neurona Therapeutics has filed 8 Form Ds with the SEC since 2014, most recently in Apr 2025 ($102 million sold to 46 investors).
Institutional holders and vehicles
2 SEC-registered funds reported 35 fair-value marks on Neurona Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Areteia Therapeutics ($1.3 billion), Parabilis Medicines ($920 million) and Bluejay Therapeutics ($820 million).
How Neurona Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Neurona Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →
Frequently asked about Neurona Therapeutics
- What is Neurona Therapeutics worth?
- Neurona Therapeutics is valued at $1.1B as of Oct 2026. Fund marks imply 1/98 of the round — treated as a units change, held — shown at a merger or acquisition, Apr 2026 ($1.1B post-money).
- How much has Neurona Therapeutics raised?
- Neurona Therapeutics has raised $347.6M in total funding across 6 recorded rounds.
- When did Neurona Therapeutics last raise?
- Neurona Therapeutics last raised in Mar 2025 (Later Stage VC (Series F)), raising $101.7M.